Eugene

[email protected]

LATEST

BI Forms $1.2-Billion Deal with Bridge Therapeutics for Lung-Disease Drug
By

By
Boehringer Ingelheim (BI) has entered into a collaboration and license agreement, in a deal worth up to in up EUR 1.1 billion ($1.2 billion), with Bridge Biotherapeutics, a clinical-stage biopharmaceutical…

Bayer to Sell Dr. Scholl’s Foot-Care Business for $585 Million
By

By
Yellow Wood Partners, a Boston-based private investment firm, has entered into a definitive agreement to buy the Dr. Scholl’s business, consisting of foot-care products, from Bayer for $585 million. Bayer…

Roche, Spark Therapeutics Update Closing Date for Their $4.3-Billion Merger
By

By
Roche and Spark Therapeutics have agreed to amend their agreement for their $4.3-billion merger to allow for a closing date through April 30, 2020 from January 31, 2020. The move…

Gilead and Galapagos Enter $5-Billion Research and Development Deal
By

By
Gilead Sciences and Galapagos, a Mechelen, Belgium-based pharmaceutical company focused on small-molecules drugs in inflammation, fibrosis, and osteoarthritis, have entered into a 10-year global research and development collaboration in a…

Gilead’s Kite to Build New Viral Vector Mfg Facility in California
By

By
Kite, a Gilead Sciences biopharmaceutical company for cancer immunotherapies, has announced plans for a 67,000-square-foot facility in Oceanside, California for the development and manufacturing of viral vectors. Viral vectors are…

BI to Acquire Biotech Company Amal Therapeutics in $365-Million Deal
By

By
Boehringer Ingelheim (BI) has agreed to acquire Amal Therapeutics, a private Swiss biotechnology company developing cancer immunotherapies and therapeutics cancer vaccines, for a total transaction value of EUR 325 million…

OTC Manufacturer PL Developments Acquires Teva’s US Store-Brand Portfolio
By

By
PL Developments (PLD), a manufacturer, packager and distributor of over-the-counter (OTC) pharmaceutical products, has acquired Teva Pharmaceuticals’ US store-brand portfolio, which includes Teva’s nicotine chewing gum. The acquisition will add…

GSK Opens New Continuous Mfg Facilities for $96 Million in Singapore
By

By
GlaxoSmithKline (GSK) has opened two continuous pharmaceutical manufacturing facilities in Jurong, Singapore following a S$130-million (US $96-million) investment. The new facilities include two continuous manufacturing facilities and an expansion of…

FDA Cites Mfg Issues in Biocon’s Insulins Facilities in Malaysia
By

By
The US Food and Drug Administration (FDA) has issued a Form 483 to Biocon’s insulin glargine manufacturing facilities in Malaysia following a pre-approval inspection conducted by the agency between June…

Aurobindo Receives FDA Warning Letter for API Mfg Violations
By

By
The US Food and Drug Administration (FDA) has issued a Warning Letter to Aurobindo Pharma for its drug-manufacturing facility in Srikakulam District, Andhra Pradesh, India, citing deviations from current good…